Friday, 15 February 2013
AstraZeneca today announced that, on 14 February 2013, the United States Court of Appeals for the Federal Circuit summarily upheld a lower court ruling that had found the formulation patent protecting SEROQUEL XR (quetiapine fumarate) extended release tablets in the US to be valid and infringed.
AstraZeneca is pleased with the appellate court’s decision, which again demonstrates the strength of the intellectual property protecting SEROQUEL XR.
NOTES FOR EDITORS
About the Seroquel XR formulation patent trial
In March 2012, the US District Court for the District of New Jersey found the formulation patent protecting SEROQUEL XR extended release tablets to be valid. The court also ruled that Anchen Pharmaceuticals, Inc., Osmotica Pharmaceutical Corporation, Torrent Pharmaceuticals Limited, Torrent Pharma Inc., Mylan Pharmaceuticals Inc. and Mylan Inc. have infringed the SEROQUEL XR formulation patent.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
|Esra Erkal-Paler||(UK/Global)||+44 20 7604 8030|
|Vanessa Rhodes||(UK/Global)||+44 20 7604 8037|
||+44 20 7604 8034
||(US)||+1 302 885 2677|
|James Ward-Lilley||+44 20 7604 8122||mob: +44 7785 432613|
|Karl Hård||+44 20 7604 8123||mob: +44 7789 654364|
||+44 20 7604 8124||mob: +44 7585 404950|
|Ed Seage||+1 302 886 4065||mob: +1 302 373 1361|
|Colleen Proctor||+1 302 886 1842||mob: +1 302 357 4882|